Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. (NASDAQ: CRVO) generates frequent news flow as a clinical-stage biotechnology company developing neflamapimod for dementia with Lewy bodies (DLB) and other age-related brain disorders. The company’s updates often center on clinical data releases, regulatory interactions, and corporate developments tied to its lead program.
Investors following CRVO news can expect detailed announcements on results from the Phase 2b RewinD-LB trial in DLB, including subgroup analyses, biomarker findings, and longer-term extension data. CervoMed has reported that neflamapimod treatment in DLB was associated with effects on the Clinical Dementia Rating – Sum of Boxes (CDR-SB), the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), and plasma biomarkers such as glial fibrillary acidic protein (GFAP), Aβ42/40 ratio, and neurofilament light. These news items provide insight into how the company interprets clinical and biomarker outcomes in its target population, particularly patients with a low likelihood of Alzheimer’s disease co-pathology.
CervoMed’s news flow also includes regulatory milestones, such as written feedback from the U.S. Food and Drug Administration aligning on key aspects of the planned Phase 3 trial design in DLB. Articles may describe planned trial parameters, enrichment strategies using plasma ptau181, and the role of CDR-SB as the primary endpoint. Additional coverage highlights participation in scientific conferences, presentations at dementia and neurology meetings, and dissemination of new analyses of trial data.
Beyond clinical and regulatory updates, CRVO news features quarterly financial results, grant funding details, and changes to the company’s leadership and board composition. Announcements of executive appointments, board expansions, and investor conference participation help contextualize CervoMed’s preparation for late-stage development and potential commercialization of neflamapimod. This news page aggregates these items so readers can track how scientific results, regulatory feedback, and corporate actions evolve over time.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston, MA. The company's management will engage in a fireside chat on Tuesday, August 12, 2025, at 2:00 PM ET.
The presentation will be available via webcast, accessible through the company's investor relations website. During the conference, which runs from August 12-14, 2025, management will also conduct one-on-one meetings with investors.
CervoMed (NASDAQ: CRVO) announced positive 32-week data from the Extension phase of the Phase 2b RewinD-LB trial for neflamapimod in treating Dementia with Lewy Bodies (DLB). The trial demonstrated a 54% risk reduction in clinically significant worsening compared to control, improving to 64% in patients with minimal Alzheimer's Disease co-pathology.
Key findings include a significant reduction in plasma levels of glial fibrillary acidic protein (GFAP) at week 32, and improved efficacy with new capsules achieving target plasma concentrations. The study showed a 40% lower rate of clinically meaningful worsening in patients receiving new capsules versus old capsules, with both formulations maintaining similar safety profiles.
CervoMed plans to meet with the FDA in Q4 2025 to discuss Phase 3 trial design for this potential treatment of the second most common form of dementia.
CervoMed (NASDAQ: CRVO), a clinical stage company focused on neurologic disorder treatments, will present new data from its Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies (DLB) at AAIC 2025.
The company will host a conference call on July 28, 2025, at 8:00 AM ET to discuss primary endpoint results at 32-weeks from the Extension phase. Investors can access the webcast through the company's website, with domestic participants dialing 1-877-425-9470 and international participants dialing 1-201-389-0878 using code 13755139.
CervoMed (NASDAQ: CRVO), a clinical stage company specializing in age-related neurologic disorders, will present late-breaking research at the Alzheimer's Association® International Congress (AAIC) 2025 in Toronto from July 27-31, 2025.
The company will showcase results from their RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) through two presentations: an in-person poster discussing effects on clinical progression in DLB patients without Alzheimer's disease co-pathology, and a virtual presentation examining the impact of AD co-pathology on treatment response.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company specializing in treatments for age-related neurologic disorders, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place in New York on May 20, 2025.
Company management will engage in a fireside chat scheduled from 5:00 to 5:30 PM ET and will also conduct one-on-one investor meetings. The fireside chat will be available via webcast through the company's website and a dedicated event platform.
CervoMed Inc. (NASDAQ: CRVO) announced positive results from the Extension phase of their Phase 2b RewinD-LB study of neflamapimod for treating dementia with Lewy bodies (DLB). The study showed that neflamapimod, when administered with New Capsules achieving target plasma concentrations, significantly slowed clinical progression compared to controls.
Key findings include:
- Improvement in Clinical Dementia Rating Sum of Boxes (CDR-SB) with New Capsules vs Old Capsules (p0.001) and vs placebo (p=0.003)Mean improvement of 0.73 points with New Capsules compared to Old Capsules
- 40% lower rate of clinical worsening in New Capsule recipients
- Improved outcomes in Alzheimer's Disease Cooperative Study (ADCS-CGIC)
- Reduced incidence of falls (4% vs 15.2%) with New Capsules
The results will be presented at the AD/PD™ 2025 conference on April 5, 2025, demonstrating proof-of-concept for neflamapimod as a DLB treatment.
CervoMed (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, announced an upcoming oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases (AP/PD™) in Vienna, Austria on April 5, 2025.
The presentation will focus on detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB). The presentation will be delivered by CEO John Alam, MD, and Stephen Gomperts, MD, PhD, from Harvard Medical School and Massachusetts General Hospital.
CervoMed (NASDAQ: CRVO) has reported its Q4 and full-year 2024 financial results, highlighting positive 16-week results from the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB). The trial showed significant improvements in the primary outcome measure.
Financial highlights include:
- Cash position of $38.9 million as of December 31, 2024 (up from $7.8M in 2023)
- Grant revenue of $9.7 million for 2024 (up from $7.1M in 2023)
- R&D expenses increased to $18.8 million (from $8.4M in 2023)
- Net loss of $16.3 million for 2024
The company plans to initiate a Phase 3 trial in mid-2026 and expects to report 32-week extension phase results in H2 2025. Current cash runway extends into mid-2026.